

FOR IMMEDIATE RELEASE:
May 4, 2017

Media Contacts:

Colin Donnelly
Massachusetts Life Sciences Center Tel: (617)-373-7726
cdonnelly@masslifesciences.com

Anke H Kreisher
Business Development - Early Clinical Trials
Cambridge, MA
Eurofins-Optimed
(717) 693-2078
AnkeKreisher@eurofinsus.com

Eurofins-Optimed Brings Clinical Trials Stateside, Opens Cambridge Office

CAMBRIDGE, Mass. — Eurofins-Optimed, a worldwide leader in early clinical trials, announced today the opening of its Boston-area office, located in the Cambridge Innovation Center (CIC) in Cambridge, Massachusetts.

Eurofins-Optimed is the Clinical Competence Center of Eurofins Group, a global leader in BioPharmaceutical product testing. The company now expects to leverage the tremendous resources of its global network in Europe, the US, and Asia to benefit biotech, pharma, and agro-food clients in the Boston area.

“As a leader in early clinical development of new drugs, Eurofins-Optimed offers a complete range of services to the pharmaceutical, biotech and medtech companies for almost 30 years” said Dr Yves Donazzolo, President and Medical Director of Eurofins-Optimed. “Our presence in Massachusetts is an exciting opportunity to expand our services and to help our clients to develop their new products by taking advantage of the stunning GXP capabilities of Eurofins services all over the world”.

“With our new presence in Cambridge, we will be able to focus on the immediate ‘early clinical trial’ needs for client companies. Our services are entirely customer configurable. Our regulatory expertise will help save our customer time and money while positioning their products for commercialization in a broad range of markets,” said Anke Kreisher, Eurofins-Optimed’s business development executive who will be based at the new office.

“Eurofins-Optimed has demonstrated expertise around the world in managing early clinical trials. We believe this expertise is a perfect complement to the unmatched volume of clinical programs being developed here in Massachusetts by our early stage companies and world-class academic medical centers,” said Travis McCready President & CEO of the Massachusetts Life Sciences Center. “On behalf of the Massachusetts Life Sciences Center, I welcome Eurofins to the Commonwealth and look forward to having a front row seat of their growth.”

“MassBio is thrilled to welcome Eurofins-Optimed to the Massachusetts life sciences supercluster,” said Robert K. Coughlin, President & CEO of MassBio. “We know that Eurofins will bring value and benefit as they connect with new partners in our robust biopharma community, which increasingly relies on the important work of contract service providers.”

About Eurofins-Optimed,

Eurofins-Optimed is located in the South East of France (Grenoble). Since 1990, the company has offered services in Early Clinical Development (phase I/II) including Site Management, Organization & Biometrics. Eurofins-Optimed follows all international requirements to carry out clinical studies – ICH recommendation, Good Clinical Practices.

Services include:

Management of Early Clinical studies with Patients, Project Management Monitoring, Site Management Organization.

Clinical studies with Healthy Volunteers and ambulatory patients in our own facilities: First into Human Studies, Pharmacokinetic studies, Bioequivalence studies, TQT/QTc studies, Interaction studies, Vaccine studies.

Biometrics: Data Management, e-CRF, Statistics, Clinical Report.

<http://www.eurofins-optimed.com/>

<http://www.eurofins.com/contact-us/worldwide-interactive-map/france/eurofins-optimed-clinical-research/>

About the Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a \$1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation’s most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences. For more information, visit www.masslifesciences.com.

MLSC Disclaimer: This announcement is not intended to be a commercial endorsement of any products or services provided or developed by the entities referenced in this release.